Paul Richards

2.2k citations

42 papers · 1.4k indexed · h-index 20

Impact in

Oncology top 5%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- PARP inhibition in cancer therapy
Genetics top 5%
- Chronic Lymphocytic Leukemia Research

Papers in

Oncology 33
- Cancer Treatment and Pharmacology 13
- HER2/EGFR in Cancer Research 12
- Global Cancer Incidence and Screening 7
- Colorectal Cancer Treatments and Studies 5
Cancer Research 13
- Breast Cancer Treatment Studies 13

Co-authors: Howard A. Burris Daniel C. Scullin John D. Hainsworth Lisa H. Morrissey Sharlene Litchy F. Anthony Greco James D. Bearden Denise A. Yardley
Journals: Journal of Clinical Oncology (9 papers)Breast Cancer Research and Treatment (4 papers)Blood (3 papers)Annals of Surgical Oncology (3 papers)British journal of surgery (3 papers)
Partner nations: United States United Kingdom Spain

In The Last Decade

Paul Richards

40 papers receiving 1.4k citations

Peers

Countries citing papers authored by Paul Richards

Since Specialization

Citations

This map shows the geographic impact of Paul Richards's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Richards with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Richards more than expected).

Fields of papers citing papers by Paul Richards

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Richards. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Richards. The network helps show where Paul Richards may publish in the future.

Co-authors

The 25 scholars most cited alongside Paul Richards, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Paul Richards Line = papers co-authored together Paul Richards links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	265P Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC) Annals of Oncology ·Sacha J. Howell, Matthew Krebs, Simon Lord, Laura Kenny, Amit Bahl, Glen Clack, Edward Ainscow, H-T. Arkenau, Janine Mansi, Carlo Palmieri, Paul Richards, Rinath Jeselsohn, Gangiang Liu, William J. Gradishar, Sagar Sardesai, Joyce O’Shaughnessy, С.Х. ДАВАНОВ, Simak Ali, Stuart McIntosh, R. Charles Coombes	2021	7
2	Adjuvant Chemotherapy for Breast Cancer in Older Women: An Analysis of Retrospective English Cancer Registration Data Clinical Oncology ·Sue Ward, Geoffrey R. Holmes, Alistair Ring, Paul Richards, Jenna Morgan, John Broggio, Karen Collins, Malcolm Reed, Lynda Wyld	2019	17
3	A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation Breast Cancer Research and Treatment ·Joyce O’Shaughnessy, Angela DeMichele, X. Cynthia, Paul Richards, Denise A. Yardley, Gail S. Wright, Kevin Kalinsky, Ronald G. Steis, Sami Diab, Gerard T. Kennealey, Ryan Geschwindt, Wei Jiang, Hope S. Rugo	2018	35
4	First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2− advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial Breast Cancer Research and Treatment ·Wolfgang Janni, Emilio Alba, Thomas Bachelot, Sami Diab, Miguel Gil‐Gil, Thaddeus Beck, Larisa Ryvo, Rafael López‐López, Michaela L. Tsai, Francisco J. Esteva, Pilar Auñón, Zdeněk Král, Patrick J. Ward, Paul Richards, Timothy Pluard, Santosh Sutradhar, Michelle C. Miller, Mario Campone	2018	35
5	Pertuzumab/Trastuzumab/CT Versus Trastuzumab/CT Therapy for HER2+ Breast Cancer: Results from the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Annals of Surgical Oncology ·Peter D. Beitsch, Pat W. Whitworth, Paul L. Baron, NT Gurusinghe, I-Te Chen, Paul Richards, Mary K. Murray, James Pellicane, K. Nilsson, F. Betti, Lisette Stork‐Sloots, Femke De Snoo, พวงน้อย อรุณ, Laura A. Lee	2017	28
6	Relation between chelation and clinical outcomes in lower-risk patients with myelodysplastic syndromes: Registry analysis at 5 years Leukemia Research ·Roger M. Lyons, Zulhimmah Mukhlis, Carole Paley, Jason Esposito, Emine Şekerdağ Kılıç, Paul Richards, Nicholas J. DiBella, Guillermo Garcia‐Manero	2017	39
7	Abstract P4-22-04: A randomized, double-blind, phase 2 study of ruxolitinib (RUX) or placebo (PBO) in combination with capecitabine (CAPE) in patients (pts) with advanced HER2-negative breast cancer (ABC) and elevated C-reactive protein (CRP), a marker of systemic inflammation Cancer Research ·Joyce O’Shaughnessy, A. DeMichele, X. Cynthia, Paul Richards, DA Yardley, Saranya Prabhasawasdi, Kevin Kalinsky, Ronald G. Steis, Sami Diab, Gerard T. Kennealey, Ryan Geschwindt, Wei Jiang, H. S. Rugo	2017	1
8	Duration of response and tumor shrinkage with first-line ribociclib + letrozole in postmenopausal women with HR+, HER2– ABC Annals of Oncology ·Wolfgang Janni, Emilio Alba, Thomas Bachelot, Joshua Fox, Miguel Gil‐Gil, Thaddeus Beck, Larisa Ryvo, (unknown), L Céline, Francisco J. Esteva, Alvin Kristopher C. Bendicio, Zdeněk Král, Patrick J. Ward, Paul Richards, Timothy Pluard, Santosh Sutradhar, Michelle C. Miller, Mario Campone	2017	1
9	The use of surgery in the treatment of ER+ early stage breast cancer in England: Variation by time, age and patient characteristics European Journal of Surgical Oncology ·Paul Richards, Sue Ward, Jenna Morgan, Catherine Lagord, Malcolm Reed, Karen Collins, Lynda Wyld	2016	21
10	Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II Study Clinical Breast Cancer ·Denise A. Yardley, James A. Reeves, Elizabeth Claire Dees, Cynthia R. Osborne, Devchand Paul, Foluso O. Ademuyiwa, Hatem Soliman, Troy H. Guthrie, Jay Andersen, Malek A. Alsulami, J. K. Choksi, Brooke Daniel, Michael Danso, Anne Favret, Karl Wellnitz, Adam Brufsky, Jane Bromund, Yong Lin, Ayman Ibrahim, Paul Richards	2016	29
11	A phase II trial of trabectedin in triple-negative and HER2-overexpressing metastatic breast cancer Breast Cancer Research and Treatment ·Joanne L. Blum, Anthony Gonçalvès, Noa Efrat, Marc Debled, Pierfranco Conté, Paul Richards, Donald Richards, Pilar Lardelli, Antonio Nieto, Martín Cullell-Young, Suzette Delaloge	2016	15
12	Impact of Tumor Size on Probability of Pathologic Complete Response After Neoadjuvant Chemotherapy Annals of Surgical Oncology ·Paul L. Baron, Peter D. Beitsch, Danielle Boselli, James T. Symanowski, James Pellicane, J. David Beatty, Paul Richards, I-Te Chen, F. Betti, Laura A. Lee, Mary K. Murray, Femke A. de Snoo, Lisette Stork‐Sloots, Mark Gittleman, Stephanie Akbari, Pat W. Whitworth	2015	24
13	Chemosensitivity Predicted by BluePrint 80-Gene Functional Subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Annals of Surgical Oncology ·Pat W. Whitworth, Lisette Stork‐Sloots, Femke A. de Snoo, Paul Richards, NT Gurusinghe, J. David Beatty, I-Te Chen, James Pellicane, Bichlien Nguyen, Laura Lee, F. Betti, Mark Gittleman, Stephanie Akbari, Peter D. Beitsch	2014	52
14	Phase III safety study of rituximab administered as a 90-minute infusion in patients with previously untreated diffuse large B-cell and follicular lymphoma Leukemia & lymphoma ·Shaker R. Dakhil, Róbert Hermann, Marshall T. Schreeder, Stephanie A. Gregory, Curtis R. Williams, Tapajós Tapajós, Deborah Hurst, Akiko Chai, Michael Brewster, Paul Richards	2014	19
15	The in vitro effects of sulfadoxine/pyrimethamine and artemether/lumefantrine on the viscoelasticity of erythrocyte membrane of healthy females Clinical Hemorheology and Microcirculation ·Paul Richards, Edna Rey-Vizgirdas, Maritza B. Torres, Garry Abfalter	2014	2
16	Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor‐targeted therapy Cancer ·Daniel C. Cho, Thomas E. Hutson, Wolfram E. Samlowski, Peter Sportelli, Brad Somer, Paul Richards, Jeffrey A. Sosman, Igor Puzanov, M. Dror Michaelson, Keith T. Flaherty, Robert A. Figlin, Nicholas J. Vogelzang	2012	36
17	Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen Breast Cancer Research and Treatment ·Denise A. Yardley, Lowell L. Hart, Linda D. Bosserman, Humairoh Tazkiyatun Nisa, David Waterhouse, Lyubov M. Semeikina, Paul Richards, Michelle DeSilvio, Janine Mahoney, Yasir M. Nagarwala	2012	33
18	Sunitinib Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel for First-Line Treatment of Patients With Advanced Breast Cancer: A Phase III, Randomized, Open-Label Trial Clinical Breast Cancer ·Nicholas J. Robert, Mansoor N. Saleh, Devchand Paul, Daniele Generali, Laurent Gressot, Mehmet S Copur, Adam Brufsky, Susan Minton, Jeffrey K. Giguere, John W. Smith, Paul Richards, Diana Gernhardt, Xin Huang, Katherine Liau, Kenneth A. Kern, Jason J. Davis	2011	94
19	Efficacy and Safety of Paclitaxel Poliglumex as First-Line Chemotherapy in Patients at High Risk with Advanced-Stage Non–Small-Cell Lung Cancer: Results of a Phase II Study Clinical Lung Cancer ·Donald Richards, Paul Richards, David Bodkin, Marcus A. Neubauer, F. B. Oldham	2005	23
20	Some observations on fluorescence in situ hybridization evaluation of chronic myelocytic leukemia Cancer Genetics and Cytogenetics ·Zhong Chen, P Careil, Paul Richards, Anshul Mathur, Rodman Morgan, John F. Stone, Avery A. Sandberg	1997	22

About Paul Richards

Paul Richards is a scholar working on Oncology, Cancer Research, Genetics, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine, having authored 42 papers that have together received 1.4k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (13 papers), Breast Cancer Treatment Studies (13 papers), HER2/EGFR in Cancer Research (12 papers), Advanced Breast Cancer Therapies (8 papers), Global Cancer Incidence and Screening (7 papers), Colorectal Cancer Treatments and Studies (5 papers), Lung Cancer Treatments and Mutations (5 papers) and Chronic Lymphocytic Leukemia Research (4 papers). The work is most often cited by research in Oncology (869 citations), Genetics (278 citations), Pathology and Forensic Medicine (438 citations), Cancer Research (342 citations) and Geriatrics and Gerontology (38 citations). Paul Richards has collaborated with scholars based in United States, United Kingdom and Spain. Frequent co-authors include Howard A. Burris, Daniel C. Scullin, John D. Hainsworth, Lisa H. Morrissey, Sharlene Litchy, F. Anthony Greco, James D. Bearden, Denise A. Yardley, Mansoor N. Saleh and Nicholas J. Robert. Their work appears in journals such as Journal of Clinical Oncology, Breast Cancer Research and Treatment, Blood, Annals of Surgical Oncology and British journal of surgery.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact